Bevacizumab-associated gastrointestinal perforation-Reference-Cited by-同舟云学术

Bevacizumab-associated gastrointestinal perforation

Published:2009-06 Issue:6 Volume:10 Page:534-536
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Chau Ian,Cunningham David

Publisher

Elsevier BV

Subject

Oncology

Reference12 articles.

1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

2. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis;Hapani;Lancet Oncol,2009

3. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy;Sugrue;Proc Am Soc Clin Oncol,2006

4. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma;Shah;J Clin Oncol,2006

5. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer;Crane;J Clin Oncol,2006

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network;Radiotherapy and Oncology;2021-02

2. Safety and Efficacy of Palliative Colorectal Stent Placement Using a Nasal Endoscope Technique;Surgical Laparoscopy, Endoscopy & Percutaneous Techniques;2015-06

3. Bevacizumab: A Review of Its Use in Advanced Cancer;Drugs;2014-10

4. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection;Annals of Oncology;2011-09

5. Response;Gastrointestinal Endoscopy;2010-12